PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Mayo Clinic, Rochester, Minnesota, USA.\', \'nference, Cambridge, Massachusetts, USA.\', \'Mayo Clinic Health System, Eau Claire, Wisconsin, USA.\', \'Mayo Clinic Health System, Mankato, Minnesota, USA.\', \'Mayo Clinic in Arizona, Phoenix, Arizona, USA.\', \'Mayo Clinic in Florida, Jacksonville, Florida, USA.\', \'Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1172/JCI151697e151697
?:doi
?:hasPublicationType
?:journal
  • The Journal of clinical investigation
is ?:pmid of
?:pmid
?:pmid
  • 34411003
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all